Zhen Zhou

Zhen Zhou

Auto-generated profile, based on publicly available information

Zhen Zhou

Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing 210008, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XSXianchao Sun
Xianchao Sun
YZYing Zhang
Ying Zhang
YCYilai Chen
Yilai Chen
SXShiyong Xin
Shiyong Xin
LJLiang Jin
Liang Jin
LYLin Ye
Lin Ye
Background. Aberrant lipid metabolism is an alteration common to many types of cancer. Dysregulation of lipid metabolism is considered a major risk factor for bladder cancer. Accordingly, we focused on genes related to lipid metabolism and screened novel markers for predicting the prognosis of bladder cancer. Methods. RNA‐seq data for bladder cancer were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The nonnegative matrix factorization (NMF) algorithm was used to classify the molecular subtypes. Weighted correlation network analysis (WGCNA) was applied to identify coexpressed genes, and least absolute shrinkage and selection operator (LASSO) multivariate Cox analysis was used to construct a prognostic risk model. External validation data and in vitro experiments were used to verify the results from in silico analysis. Results. Bladder cancer samples were grouped into two clusters based on the NMF algorithm. A total of 1467 genes involved in coexpression modules were identified in WGCNA. We finally established a 5‐gene signature (TM4SF1, KCNK5, FASN, IMPDH1, and KCNJ15) that exhibited good stability across different datasets and was also an independent risk factor for prognosis. Furthermore, the predictive efficacy of our model was generally higher than the predictive efficacy of other published models. Distinct risk groups of patients also showed significantly different immune infiltration cell patterns and associations with clinical variables. Moreover, the 5 signature genes were verified in clinical samples by quantitative real‐time polymerase chain reaction (qRT‐PCR) and immunohistochemistry, which were in agreement with the in silico analysis. For in vitro experiments, knockdown of IMPDH1 markedly inhibited cell proliferation in bladder cancer. Conclusion. We established a 5‐gene prognosis signature based on lipid metabolism in bladder cancer, which could be an effective prognostic indicator.

16 March 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
ZZZhen Zhou
Zhen Zhou
FYFeng Yue
Feng Yue
LJLiang Jin
Liang Jin
XLXiang Liu
Xiang Liu
TZTing-Shuai Zhai
Ting-Shuai Zhai
LYLin Ye
Lin Ye
Objective: We aimed to evaluate the role of tumor size in predicting tumor risk for localized prostate cancer (PCa) patients undergoing radical prostatectomy (RP).Methods: Twenty‐five thousand, one hundred twenty‐seven men with PCa receiving RP from 2010 to 2015 were extracted from the Surveillance, Epidemiology, and End Results database. Kaplan–Meier plots and multivariable Cox regression analyses were used to illustrate overall survival (OS) according to the tumor size. The tumor size was confirmed by postoperative pathology after RP.Results: Among overall localized PCa, 84.6% were high‐risk PCa, 9.2% were intermediate‐risk PCa, and 6.2% were low‐risk PCa. Multivariate analyses demonstrated that tumor size ≥21 mm was an independent risk predict factor of low‐risk PCa (odds ratio [OR]: 11.940; 95% CI, 9.404–15.161; p < 0.001) and intermediate‐risk PCa (OR: 1.887; 95% CI, 1.586–2.245; p < 0.001). Tumor sizes ≤5 mm significantly correlated with high‐risk PCa (p < 0.001). Tumor size ≤5 mm had the worst OS in overall localized PCa and high‐risk PCa (p < 0.001).Conclusions: In localized PCa, tumor sizes ≥21 mm may help predict low or intermediate‐risk PCa, while tumor sizes ≤5 mm might help predict high‐risk PCa. In clinical practice, we should be on high alert for patients with tumors size ≤5 mm due to its poor prognosis after RP.

17 March 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
SXShiyong Xin
Shiyong Xin
XSXianchao Sun
Xianchao Sun
LJLiang Jin
Liang Jin
ZZZhen Zhou
Zhen Zhou
XLXiang Liu
Xiang Liu
LYLin Ye
Lin Ye
The platelet-derived growth factor (PDGF) pathway is important in angiogenesis, which can accelerate the formation of vessels in tumor tissues and promote the progression of malignant tumors. To clarify the role of PDGF in the occurrence of renal cell carcinoma and targeted drug resistance, we explored the pathway in kidney renal clear cell carcinoma (KIRC) through bioinformatics analysis with the aim of supporting comprehensive and individualized therapy. First, we found 40 genes related to the PDGF pathway through gene set enrichment analysis and then obtained their expressions and clinical data in 32 different cancers from The Cancer Genome Atlas (TCGA). Mutations in these genes (including copy number and single-nucleotide variation) and mRNA expression were also detected. Next, we conducted a hazard ratio analysis to determine whether the PDGF pathway genes were risk or protective factors in tumors. Although PDGF-related genes acted as traditional oncogenes and were closely related to tumor angiogenesis in many cancers, our results indicated that most genes had a protective role in KIRC. We further analyzed the methylation modification of PDGF pathway genes and found that they were prevalent in 32 different cancers. Furthermore, 539 KIRC samples obtained from TCGA were divided into three clusters based on the mRNA expression of PDGF genes, including normal, inactive, and active PDGF gene expressions. The results from survival curve analysis indicated that the active PDGF cluster of patients had the best survival rate. Using the three clusters, we studied the correlation between the PDGF pathway and 12 common targeted drugs, as well as classical oncogenes and infiltrating immune cells. A prognostic risk model was constructed based on the PDGF score using LASSO-Cox regression analysis to analyze the value of the model in predicting the prognosis of patients with KIRC. Finally, 11 genes were selected for LASSO regression analysis, and the results demonstrated the high predictive value of this risk model and its close relationship with the pathological characteristics of KIRC (metastasis, size, grade, stage, etc.). In addition, we found that the risk score was an independent risk factor correlated with overall survival through univariate and multivariate analyses and a nomogram was built to assess patient prognosis. In conclusion, the occurrence and development of KIRC may be associated with an abnormally activated PDGF pathway, which may be a potential drug target in the treatment of KIRC.

8 July 2022 in Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology
Verified
Journal Article
Closed access
SPS S Peng
S S Peng
HWH Y Wu
H Y Wu
JYJ Yang
J Yang
QSQ Y Sun
Q Y Sun
ZZZ Y Zhou
Z Y Zhou
XFXiangshan Fan
Xiangshan Fan